Company news

Imugene Ltd news in 2025

Imugene Ltd's news releases, calls and decks from 2025, newest first.

View company

FDA Supports Strategy Toward Registration for Azer-cel

December 7, 2025

Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours

November 27, 2025

Strategic Collaboration with JW Therapeutics

November 26, 2025

S&P DJI Announces September 2025 Quarterly Rebalance

September 5, 2025

Final Share Purchase Plan Allotment

August 28, 2025

Appendix 4E and Annual Report

August 25, 2025

Imugene Capital Raising Presentation

July 16, 2025

Imugene Completes $22.5M Placement and c.$15M SPP

July 16, 2025

Imugene Announces Outstanding Response Rates from the Phase 1b Trial of the Azer-cel Allogeneic CAR T in 3L+ DLBCL

July 14, 2025

Two Additional Complete Responses in azer-cel Ph1b trial

July 13, 2025

Notice of Extraordinary General Meeting/Proxy Form

May 27, 2025

Azer-cel Granted FDA Fast Track Designation in Blood Cancer

March 18, 2025

S&P DJI Announces March 2025 Quarterly Rebalance

March 7, 2025

Imugene Granted India Patent for Oncolytic Virotherapy CF33

February 26, 2025

Imugene OnCARlytics Patent Allowance in China

February 25, 2025

Azer-cel demonstrates two additional Complete Responses

February 13, 2025

Imugene Receives A$20 million for Convertible Notes Issuance

January 28, 2025

Imugene Receives $11.7m R&D Tax Refund

January 10, 2025

First Australian Patient Dosed in Phase 1b azer-cel Trial

January 2, 2025

Decks in 2025